Agenus Announces ESMO Oral Presentation of Two Clinical Trials of Balstilimab Alone and in Combination with Zalifrelimab in Recurrent or Metastatic Cervical Cancer

Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapy, adjuvants, and vaccines designed to activate immune response to cancers…

Read the full article here

Related Articles